Table 1 Characteristics of patients with ovarian cancer and comparison with pretreatment HE4 and CA125 level
Characteristics | Pretreatment HE4 Mean (range) [pmol/L] | Pretreatment CA125 Mean (range) [U/ml] |
|---|---|---|
Menopausal | ||
Premenopausal, n=35 | 408.8 (32.4–1529) | 939.3 (9.0–5023) |
Postmenopausal, n=54 | 548.7 (47.4–4703) | 855.4 (8.0–4423) |
P value | 0.309 | 0.733 |
FIGO stage | ||
I and II, n=37 | 286.7 (32.4–1500) | 543.8 (8.0–3066) |
III and IV, n=52 | 641.0 (63.11–4703) | 1133.5 (18.8–5023) |
P value | 0.008 | 0.008 |
Tumor grade | ||
1, n=11 | 141.2 (33.6–437) | 472.0 (9.0–2062) |
2 and 3, n=78 | 543.4 (32.4–4703) | 947.1 (683.6–1210) |
P value | 0.000 | 0.191 |
Histology | ||
Serous, n=48 | 618.5 (47.4–4703) | 1152.6 (8.0–5023) |
Mucinous, n=7 | 232.5 (40.8–1132) | 139.7 (12.5–523) |
Clear cell, n=11 | 193.9 (32.4–675) | 229.4 (13.0–653) |
Endometrioid, n=8 | 635.7 (33.6–1529) | 714.9 (9.0–1974) |
Others, n=15 | 360.2 (81.4–1234) | 967.9 (11.68–3643) |
P value | 0.153 | 0.040 |
Platinum response | ||
Sensitive, n=73 | 487.9 (32.4–4703) | 955.2 (8.0–5023) |
Resistant, n=16 | 520.2 (63.11–1500) | 583.5 (15.6–2880) |
P value | 0.854 | 0.233 |
Two-year PFS | ||
YES, n=59 | 389.7 (32.4–2106) | 898.6 (7.98–5023) |
NO, n=30 | 698.1 (63.11–4703) | 868.2 (15.6–3643) |
P value | 0.076 | 0.905 |